Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy

Clinical Genetics

Volumn 62, Issue 2, 2002, Pages 128-134

  Yoon, H J ^a   Kim, H ^b   Kim, H L ^c   Lee, S G ^d,e   Zheng, S H ^d,e   Shin, J H ^e   Lim, C S ^d   Kim, S ^d   Lee, J S ^d   Lee, D S ^d   Kim, Yon Su ^d,e  

^a Seoul Clinical Genomics Inc   (South Korea)

^b Seoul National University   (South Korea)

^c Chosun University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

Author keywords

Angiotensin; Converting enzyme; IgA nephropathy; Platelet activating factor acetylhydrolase; Polymorphism; Prognosis; Progression

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALANINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENOMIC DNA; IMMUNOGLOBULIN A; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VALINE;

ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; EXON; FOLLOW UP; GENE DELETION; GENE FUNCTION; GENE INSERTION; GENETIC ANALYSIS; GENETIC CODE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; FEMALE; GENE FREQUENCY; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; MALE; PEPTIDYL-DIPEPTIDASE A; PHOSPHOLIPASES A; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS;

INSERTION SEQUENCES;

EID: 0036705901     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2002.620205.x     Document Type: Article

References (19)

1. Hsu SI, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 2000: 57: 1818-1835.
2. Camussi G, Pawlowski I, Saunders R, Brentjens J, Andres G. Receptor antagonist of platelet activating factor inhibits inflammatory injury induced by in situ formation of immune complexes in renal glomeruli and in the skin. J Lab Clin Med 1987: 110: 196-206.
3. Chen WP, Chen A, Lin CY. In vitro effects of interleukins on human mesangial cells: implications for glomerulonephritis. J Pathol 1995: 175: 327-337.
4. Denizot Y, Aupetit C, Bridoux F, Alphonse JC, Cogne M, Aldigier JC. Deregulated platelet-activating factor levels and acetylhydrolase activity in patients with idiopathic IgA nephropathy. Nephrol Dial Transplant 2000: 15: 1344-1347.
5. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke 1997: 28: 2417-2420.
6. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998: 47: 177-181.
7. Kruse S, Mao XQ, Heinzmann A et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 2000: 66: 1522-1530.
8. Tanaka R, Iijima K, Xu H et al. Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy. Am J Kidney Dis 1999: 34: 289-295.
9. Pei Y, Scholey J, Thai K, Suzuki M, Cattran D. Association of angiotensinogen gene T235 variant with progression of immunoglobulin A nephropathy in Caucasian patients. J Clin Invest 1997: 100: 814-820.
10. Klahr S, Morrissey J. Angiotensin II and gene expression in the kidney Am J Kidney Dis 1998: 31: 171-176.
11. Neuwirth R, Satriano JA, DeCandido S, Clay K, Schlondorff D. Angiotensin II causes formation of platelet activating factor in cultured rat mesangial cells. Circ Res 1989: 64: 1224-1229.
12. Kawaguchi H, Sawa H, Yasuda H. Mechanism of increased angiotensin-converting enzyme activity stimulated by platelet-activating factor. Biochim Biophys Acta 1990: 1052: 503-508.
13. Perico N, Lapinski R, Konopka K, Aiello S, Noris M, Remuzzi G. Platelet-activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney. J Am Soc Nephrol 1997: 8: 1391-1398.
14. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucl Acids Res 1992: 20: 1433.
15. Fernandez-Llama P, Poch E, Oriola J et al. Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998: 53: 1743-1747.
16. Yoshida H, Mitarai T, Kawamura T et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995: 96: 2162-2169.
17. Frimat L, Philippe C, Maghakian MN et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS - a study of 274 men. J Am Soc Nephrol 2000: 11: 2062-2067.
18. Tiret L, Cambien F. Departure from Hardy-Weinberg equilibrium should be systematically tested in studies of association between genetic markers and disease. Circulation 1995: 92: 3364-3365.
19. Kim DK, Kim JW, Kim S et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 1997: 17: 3242-3247.